BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 9131271)

  • 1. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients.
    Grøndahl-Hansen J; Hilsenbeck SG; Christensen IJ; Clark GM; Osborne CK; Brünner N
    Breast Cancer Res Treat; 1997 Apr; 43(2):153-63. PubMed ID: 9131271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen activator inhibitor type 1 in cytosolic tumor extracts predicts prognosis in low-risk breast cancer patients.
    Grøndahl-Hansen J; Christensen IJ; Briand P; Pappot H; Mouridsen HT; Blichert-Toft M; Danø K; Brünner N
    Clin Cancer Res; 1997 Feb; 3(2):233-9. PubMed ID: 9815678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
    Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
    J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of urokinase plasminogen activator and plasminogen activator inhibitor-1 mRNA expression in lymph node- and hormone receptor-positive breast cancer.
    Leissner P; Verjat T; Bachelot T; Paye M; Krause A; Puisieux A; Mougin B
    BMC Cancer; 2006 Aug; 6():216. PubMed ID: 16945123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.
    Descotes F; Riche B; Saez S; De Laroche G; Datchary J; Roy P; André J; Bobin JY
    Clin Breast Cancer; 2008 Apr; 8(2):168-77. PubMed ID: 18621614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Br J Cancer; 1994 Feb; 69(2):398-405. PubMed ID: 8297742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The complex between urokinase and its type-1 inhibitor in primary breast cancer: relation to survival.
    Pedersen AN; Christensen IJ; Stephens RW; Briand P; Mouridsen HT; Danø K; Brünner N
    Cancer Res; 2000 Dec; 60(24):6927-34. PubMed ID: 11156392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
    Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
    J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of urokinase-type plasminogen activator and 2 inhibitors PAI-1 and PAI-2 in breast cancer].
    Bouchet C; Spyratos F; Martin PM; Hacène K; Gentile A; Oglobine J
    Bull Cancer; 1994 Sep; 81(9):770-9. PubMed ID: 7703566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.